TRPV1 and Miyoshi myopathy: In addition, AMG9810 synergizes with proteasome inhibitors (i.e., bortezomib and carfilzomib) and overcomes bortezomib resistance in MM cells, suggesting that TRPV1 inhibition may represent a new strategy for MM treatment [63] (see “Ion Channels Inhibition as ANTI-myeloma Therapy” section).